Fate Therapeutics (FATE) Misses Q1 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.63 million versus the consensus estimate of $2.37 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Genco rejects Diana Shipping bid, calls offer below NAV
• Keefe, Bruyette & Woods Downgrades Crescent BDC (CCAP) to Market Perform